Antibodies

17 Dec 2016 European Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations
14 Dec 2016 CytomX Announces U.S. FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Study of Anti-PD-L1 Probody Therapeutic, CX-072
14 Dec 2016 European Commission Grants Marketing Authorization for Arzerra® (ofatumumab) in combination with Fludarabine and Cyclophosphamide in Relapsed CLL
13 Dec 2016 AnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020
13 Dec 2016 MacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC
13 Dec 2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor
13 Dec 2016 PlantForm to receive Government of Canada funding to advance HIV antibody research
12 Dec 2016 Immunomedics Announces Novel Immuno-Oncology Program Targeting Trop-2-Expressing Cancers
12 Dec 2016 Interim analysis of phase Ib/II study of eribulin and pembrolizumab combination regimen in metastatic triple negative breast cancer presented at San Antonio Breast Cancer Symposium
11 Dec 2016 Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in Patients with Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
10 Dec 2016 Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
10 Dec 2016 AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB
10 Dec 2016 C2N Diagnostics Reports Phase 1 Study Results of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – in Subjects with Progressive Supranuclear Palsy
10 Dec 2016 Adimab Scientists Report the Isolation of Highly Potent anti-RSV Antibodies
10 Dec 2016 BioInvent terminates current BI-505 Phase II study
10 Dec 2016 US FDA accepts first biologics license application for AstraZeneca’s durvalumab in bladder cancer
09 Dec 2016 Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting
08 Dec 2016 Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
08 Dec 2016 Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint
08 Dec 2016 Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
07 Dec 2016 KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
07 Dec 2016 Alopexx Oncology Presents Encouraging Results Of A Phase I Study Of DI-Leu16-IL2 In Relapsed/Refractory NHL At The American Society Of Hematology Annual Meeting
07 Dec 2016 Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
07 Dec 2016 FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
06 Dec 2016 Immunomedics Introduces New Antibody-Drug Conjugate at Annual Meeting of American Society of Hematology

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top